Skip to main content
An official website of the United States government
Government Funding Lapse
Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted.

The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit cc.nih.gov.

Updates regarding government operating status and resumption of normal operations can be found at opm.gov.

GD2CART for the Treatment of H3K27M Mutated Diffuse Intrinsic Pontine Glioma or Spinal Diffuse Midline Glioma

Trial Status: active

This phase I trial investigates the side effects and best dose of autologous GD2 chimeric antigen receptor (CAR) T cells (GD2CART) and how well it works in treating patients with diffuse intrinsic pontine glioma or spinal diffuse midline glioma. The chimeric antigen receptor (CAR) is a genetically-engineered receptor made so that immune cells can recognize and respond to a specific molecule, which in this trial is the GD2 protein. This uses a portion of an antibody to GD2 and part of a molecule that activates or ‘turns on’ the immune cell. The CAR molecule is combined with a patient's T cells, to help the T cells find cancer in the body. Drugs used in chemotherapy, such as cyclophosphamide and fludarabine, are given before GD2CART to help prepare the immune system to accept GD2CART, and may help let the GD2CART grow in the body and attack cancer cells. The purpose of this trial is to test the safety of giving GD2CART to children and young adults with diffuse intrinsic pontine glioma or diffuse midline glioma, and determine its effects, both good and bad, and to test how the cancer responds to GD2CART after chemotherapy.